Ginkgo Bioworks Holdings, Inc. reports developments around cell engineering, autonomous laboratory infrastructure, and contract research services that make biological R&D more programmable. Its updates cover Ginkgo Cloud Lab, Datapoints and Solutions services, Reconfigurable Automation Carts, Catalyst automation software, and AI-enabled workflows for protein engineering, nucleic acid design, cell-free systems, and biological manufacturing.
Company news also includes financial-results presentations, customer and research collaborations, agricultural biotechnology manufacturing work, and capital or governance updates. Following the completed divestiture of its Biosecurity business, recurring coverage centers on Ginkgo's autonomous lab strategy, remote wet-lab access, microbial strain engineering, fermentation processes, and the commercial use of lab-generated biological data.
Ginkgo Bioworks (NYSE: DNA) will provide in-kind access to its Boston autonomous laboratory for researchers participating in the NSF X-Labs program.
X-Labs is a $1.5 billion, decade-long initiative funding independent research teams through milestone-based awards. Ginkgo will contribute cloud lab time, allowing teams to design, run and analyze experiments remotely using robotic infrastructure. It will also offer protein testing services to express and characterize protein designs, including those generated by AI models, without researchers building their own wet laboratory capacity.
Ginkgo Bioworks (NYSE: DNA) and Araceli Biosciences have integrated Araceli's Endeavor cellular imaging instrument into Ginkgo's autonomous Nebula laboratory in Boston.
The instrument adds cellular imaging with real-time analysis to Nebula's existing technologies, generating datasets for training and validating drug discovery AI models. Endeavor images a 1536-well plate in under four minutes and runs continuously alongside Nebula's experiments. It connects to the laboratory's Reconfigurable Automation Carts, modular units combining robotic arms, automated sample transport and shared control software.
Ginkgo Bioworks (DNA) and Apheris launched an antibody developability consortium with AbbVie, argenx, Lundbeck and Takeda as founding members.
The consortium aims to build a standardized dataset of 10,000 antibodies. Each founding member will contribute proprietary antibody sequences, and Ginkgo Datapoints will fill any remaining capacity from public sources. Ginkgo will oversee antibody production and laboratory testing, then train a model on the resulting data to help assess whether antibody candidates can be developed and manufactured. Apheris will provide infrastructure that lets members use and refine models without exposing their raw proprietary sequences to one another. The initial dataset is targeted for delivery to members by early 2027.
Ginkgo Bioworks (DNA) announced that its Ginkgo Datapoints offering has entered into an agreement with Lilly’s AI/ML drug discovery platform TuneLab. Ginkgo Datapoints will provide biological discovery data generation services, including small molecule ADME and antibody developability testing, to companies participating in TuneLab. The goal is to link TuneLab’s predictive AI models with Ginkgo’s automated, high-throughput lab capabilities, turning AI-generated hypotheses into validated experimental data in days instead of months. Standardized assay protocols across the TuneLab network are expected to make models learn more efficiently and allow new TuneLab members to submit Datapoints-generated data for additional model benefits.
Ginkgo Bioworks (DNA) has been awarded a subcontract for up to $17.5 million under ARPA-H’s Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, as part of the ESCALATOR initiative to develop an autonomous, benchtop RNA drug manufacturing system.
Ginkgo will supply automation hardware, systems integration and control software that link four custom manufacturing modules and an in-line quality control subsystem of about twenty instruments. Using its Reconfigurable Automation Carts and Catalyst software, Ginkgo plans to unify control, automate manufacturing and QC protocols, and enable automated product quality decisions suitable for GMP environments. Work is expected to start following a technical kickoff later this month.
Ginkgo Bioworks (NYSE: DNA), Tangible Scientific, and Inductive Bio launched ADME-One™, a high-throughput Tier 1 ADME platform integrating automated data generation, AI-driven human PK projection, and compound management.
The U.S.-based service targets earlier, data-rich small molecule decision-making at pricing described as several times lower than typical industry options.
Ginkgo Bioworks (NYSE: DNA) reported Q1 2026 results and completed the divestiture of its Biosecurity business on April 3, 2026, presenting that unit as discontinued operations.
Key metrics: Q1 revenue $19M (down 49% vs. prior year), GAAP net loss $76M, Adjusted EBITDA $(42)M, and $373M in cash, cash equivalents and marketable securities as of March 31, 2026. Full‑year 2026 cash burn is reaffirmed at $(150)M–$(125)M. Management reiterated focus on scaling its Nebula autonomous lab.
Ginkgo Bioworks (NYSE: DNA) will present first-quarter 2026 results on Thursday, May 7, 2026 at 4:30 p.m. ET with a post-market presentation and Q&A. The live webcast and presentation details will be available on the company investor relations site, and a replay will be posted afterward.
Investors can submit questions in advance via X @Ginkgo with hashtag #GinkgoResults or by email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) launched Ginkgo Cloud Lab on March 2, 2026, a web interface giving researchers remote access to Ginkgo's autonomous lab infrastructure.
Cloud Lab runs on proprietary Reconfigurable Automation Carts (RACs), a fleet of >70 instruments, and an AI agent called EstiMate that assesses protocol compatibility and provides pricing. Ginkgo said it will migrate R&D services onto its Nebula autonomous lab and decommission traditional benches.
Ginkgo Bioworks (NYSE: DNA) reported fourth-quarter 2025 revenue of $33M (down 24% YoY) and GAAP net loss of $81M. Full-year 2025 revenue was $170M (down 25%); GAAP net loss $313M. Adjusted EBITDA improved to $(167)M FY. Cash and marketable securities totaled $423M at year-end. The company announced a planned divestiture of its biosecurity business to a consortium for a minority equity stake, expected to close in H1 2026, and will concentrate investments on building and commercializing autonomous labs. 2026 cash burn guidance: $(150)M–$(125)M.